MCMartin Christian

Martin Christian

*This is an algorithmically generated author record based on publicly available information.

Martin Christian has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Daily low-dose prednisolone to prevent relapse of steroid-sensitive nephrotic syndrome in children with an upper respiratory tract infection: PREDNOS2 RCT

    by Martin T Christian, Nicholas Ja Webb, Rebecca L Woolley, Nafsika Afentou, Samir Mehta, Emma Frew, Elizabeth A Brettell, Adam R Khan, David V Milford, Detlef Bockenhauer, et al.

    Background: Most children with steroid-sensitive nephrotic syndrome have relapses that are triggered by upper respiratory tract infections. Four small trials, mostly in children already taking maintenance corticosteroid in countries of different upper respiratory tract infection epidemiology, showed that giving daily low-dose prednisone/prednisolone for 5–7 days during an upper respiratory tract infection reduces the risk of relapse. Objectives: To determine if these findings were replicated in a large UK population of children with relapsing steroid-sensitive nephrotic syndrome on different background medication or none. Design: A randomised double-blind placebo-controlled trial, including a cost-effectiveness analysis. Setting: A total of 122 UK paediatric departments, of which 91 recruited patients. Participants: A total of 365 children with relapsing steroid-sensitive nephrotic syndrome (mean age 7.6 ± 3.5 years) were randomised (1 : 1) according to a minimisation algorithm based on background treatment. Eighty children completed 12 months of follow-up without an upper respiratory tract infection. Thirty-two children were withdrawn from the trial (14 prior to an upper respiratory tract infection), leaving a modified intention-to-treat analysis population of 271 children (134 and 137 children in the prednisolone and placebo arms, respectively). Interventions: At the start of an upper respiratory tract infection, children received 6 days of prednisolone (15 mg/m2) or an equivalent dose of placebo. Main outcome measures: The primary outcome was the incidence of first upper respiratory tract infection-related relapse following any upper respiratory tract infection over 12 months. The secondary outcomes were the overall rate of relapse, changes in background treatment, cumulative dose of prednisolone, rates of serious adverse events, incidence of corticosteroid adverse effects, change in Achenbach Child Behaviour Checklist score and quality of life. Analysis was by intention-to-treat principle. The cost-effectiveness analysis used trial data and a decision-analytic model to estimate quality-adjusted life-years and costs at 1 year, which were then extrapolated over 16 years. Results: There were 384 upper respiratory tract infections and 82 upper respiratory tract infection-related relapses in the prednisolone arm, and 407 upper respiratory tract infections and 82 upper respiratory tract infection-related relapses in the placebo arm. The number of patients experiencing an upper respiratory tract infection-related relapse was 56 (42.7%) and 58 (44.3%) in the prednisolone and placebo arms, respectively (adjusted risk difference –0.024, 95% confidence interval –0.14 to 0.09; p = 0.70). There was no evidence that the treatment effect differed when data were analysed according to background treatment. There were no significant differences in secondary outcomes between treatment arms. Giving daily prednisolone at the time of an upper respiratory tract infection was associated with increased quality-adjusted life-years (0.9427 vs. 0.9424) and decreased average costs (£252 vs. £254), when compared with standard care. The cost saving was driven by background therapy and hospitalisations after relapse. The finding was robust to sensitivity analysis. Limitations: A larger number of children than expected did not have an upper respiratory tract infection and the sample size attrition rate was adjusted accordingly during the trial. Conclusions: The clinical analysis indicated that giving 6 days of daily low-dose prednisolone at the time of an upper respiratory tract infection does not reduce the risk of relapse of steroid-sensitive nephrotic syndrome in UK children. However, there was an economic benefit from costs associated with background therapy and relapse, and the health-related quality-of-life impact of having a relapse. Future work: Further work is needed to investigate the clinical and health economic impact of relapses, interethnic differences in treatment response, the effect of different corticosteroid regimens in treating relapses, and the pathogenesis of individual viral infections and their effect on steroid-sensitive nephrotic syndrome. Trial registration: Current Controlled Trials ISRCTN10900733 and EudraCT 2012-003476-39. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 26, No. 3. See the NIHR Journals Library website for further project information.


  • Open Access

    Evaluation of Daily Low-Dose Prednisolone During Upper Respiratory Tract Infection to Prevent Relapse in Children With Relapsing Steroid-Sensitive Nephrotic Syndrome

    by Martin T. Christian, Nicholas J. A. Webb, Samir Mehta, Rebecca L. Woolley, Nafsika Afentou, Emma Frew, Elizabeth A. Brettell, Adam R. Khan, David V. Milford, Detlef Bockenhauer, et al.

    Steroid-sensitive nephrotic syndrome (SSNS) is the most common glomerular disease of childhood, with an incidence of approximately 2 per 100 000 children, although it is up to 6 times more common in children of South Asian ethnic origin.1 At least 80% of children with SSNS will relapse,2 and relapses are associated with a risk of significant complications, including sepsis, thrombosis, dyslipidemia, and malnutrition.3 At least 50% of relapses follow intercurrent infections, most commonly upper respiratory tract infections (URTIs)4-6; furthermore, in children with relapsing SSNS, half or more URTIs will trigger a relapse.7


  • Open Access

    Clinical practice guidelines standardisation of immunosuppressive and anti-infective drug regimens in UK paediatric renal transplantation: the harmonisation programme

    by Jan Dudley, Martin Christian, Alice Andrews, Nicola Andrews, Julie Baker, Sheila Boyle, Mairead Convery, Fiona Gamston, Martin Garcia, Shuman Haq, et al.


  • Optimizing the corticosteroid dose in steroid-sensitive nephrotic syndrome

    by Martin T. Christian, Andrew P. Maxted

    The use of corticosteroids in the treatment of steroid-sensitive nephrotic (SSNS) syndrome in children has evolved surprisingly slowly since the ISKDC consensus over 50 years ago. From a move towards longer courses of corticosteroid to treat the first episode in the 1990s and 2000s, more recent large, well-designed randomized controlled trials (RCTs) have unequivocally shown no benefit from an extended course, although doubt remains whether this applies across all age groups. With regard to prevention of relapses, daily ultra-low-dose prednisolone has recently been shown to be more effective than low-dose alternate-day prednisolone. Daily low-dose prednisolone for a week at the time of acute viral infection seems to be effective in the prevention of relapses but the results of a larger RCT are awaited. Recently, corticosteroid dosing to treat relapses has been questioned, with data suggesting lower doses may be as effective. The need for large RCTs to address the question of whether corticosteroid doses can be reduced was the conclusion of the authors of the recent corticosteroid therapy for nephrotic syndrome in children Cochrane update. This review summarizes development in thinking on corticosteroid use in SSNS and makes suggestions for areas that merit further scrutiny.


  • Open Access

    Children’s, parents’ and other stakeholders’ perspectives on early dietary self-management to delay disease progression of chronic disease in children: a protocol for a mixed studies systematic review with a narrative synthesis

    by Pearl Pugh, Pippa Hemingway, Martin Christian, Gina Higginbottom

    Chronic disease of childhood may be delayed by early dietary intervention. The purpose of this systematic review is to provide decision-makers with a perspective on the role of early dietary intervention, as a form of self-management, to delay disease progression in children with early chronic disease, as described by children, parents and other stakeholders. The study will systematically review empirical research (qualitative, quantitative and mixed method designs), including grey literature, using a narrative synthesis. A four-stage search process will be conducted involving a scoping search, the Scottish Intercollegiate Guidelines Network (SIGN) Patient Issues search filter on MEDLINE, the search of seven databases using a chronic disease and chronic kidney disease (CKD) search strategy, and hand searching the reference lists of identified papers for additional studies. All studies retrieved during the search process will undergo a screening and selection process against the inclusion/exclusion criteria. Methodological quality of relevant studies will be assessed using a validated Mixed Studies Review scoring system, before inclusion in the review. Relevant grey literature will be assessed for methodological quality and relative importance using McGrath et al.’s framework and the Academy Health advisory committee categories, respectively. Data extraction will be guided by the Centre for Review and Dissemination guidance and Popay et al.’s work. The narrative synthesis of the findings will use elements of Popay et al.’s methodology of narrative synthesis, applying recognised tools for each of the four elements: (1) developing a theory of how the intervention works, why and for whom; (2) developing a preliminary synthesis of findings of included studies; (3) exploring relationships in the data; and (4) assessing the robustness of the synthesis. This mixed studies systematic review with a narrative synthesis seeks to elucidate the gaps in current knowledge and generate a fresh explanation of research findings on early dietary self-management in chronic disease, with particular application to CKD, from the stakeholders’ perspective. The review will provide an important platform to inform future research, identifying the facilitators and barriers to implementing early dietary interventions. Ultimately, the review will contribute vital information to inform future improvements in chronic disease. The lead author has a particular interest in CKD paediatric service delivery. The review has been registered with PROSPERO (CRD42017078130).


  • Renal failure from birth—AKI or CKD? Answers

    by Sean Carter, Abhijit Dixit, Andrew Lunn, Anjum Deorukhkar, Martin Christian


  • Renal failure from birth—AKI or CKD? Questions

    by Sean Carter, Abhijit Dixit, Andrew Lunn, Anjum Deorukhkar, Martin Christian

    A case is presented of a neonate born at 32 weeks of gestation with intra-uterine growth retardation. The renal scan performed at 31 weeks showed oligohydramnios but normal kidneys. The neonate was oliguric from birth and required early peritoneal dialysis. Her urine showed heavy proteinuria, and the plasma albumin was very low. Post-natal ultrasonography showed large bright kidneys with reduced corticomedullary differentiation but no dysplastia; arterial and venous flow was normal on Doppler ultrasound. The quiz discusses the differential diagnosis with particular reference to whether this picture represents acute kidney injury with expected improvement or chronic kidney disease. Further questions discuss mechanisms of renal failure in this situation. Finally, with reference to previous case reports and series, a correlation between a specific mutation and this severe phenotype is proposed.

  • Open Access

    G255(P) Where there is no specialist – advocating for children with nephrotic syndrome in rural bangladesh

    by R Rhodes, M Christian, H Imam, S Sarker, A Cowper, Lt Day

    Background Although global child health focuses mainly on child survival priorities, addressed through Integrated Management of Childhood Illness, some common chronic diseases emerge. Nephrotic Syndrome (NS) in children of the Indian sub-continent is six times more prevalent than in white children. Most children have steroid-sensitive disease, presumed to be minimal change disease. In rural areas of low income countries, the early stages of NS are often not recognised by carers and presentation to appropriate medical services occurs late, when serious complications (ascites, thrombosis, infection, hypertension) are already present. Furthermore, concomitant presentation with malnutrition makes clinical assessment more difficult. This project aimed to describe the demographics and complications of children needing admission at a developing paediatric nephrotic service in rural Bangladesh. Method A retrospective review of medical records of children admitted with NS between January 2008 and April 2014 was undertaken. Results As the quality of outpatient service improved with in-service training, structured proformas and guideline-based management, increasing numbers of patients presented. Most were successfully managed as outpatients but there were 79 admissions in 67 children (0.5% of all paediatric admissions). More children presented in the cool season in contrast to the usual increase in paediatric admissions during rainy season. There was an expected 2:1 male:female ratio but, less typically, a bimodal age distribution, peaking at 3 and 9 years. Median (IQ range) duration of inpatient admissions was 8 (5–12) days. 8 children (10%) received treatment for sepsis. 22 admissions (28%) were for first presentations, 27 (34%) were for subsequent relapses and 27 (34%) had received treatment elsewhere for an unknown number of previous relapses. 3 cases lacked record of this detail. Telemedicine advice from a UK specialist was taken for complex cases. There were 4 deaths. Conclusion In a rapidly changing world, common chronic diseases in the low income setting are emerging as important causes of morbidity and mortality. Establishing a quality, resource-appropriate service for children with NS is important to build trust and relationships which promote good follow-up and early diagnosis of relapse.